In recent years, targeted therapy and immune checkpoint blockade for cancer have emerged as research hotspots in the field of tumor immunotherapy, particularly targeting immune checkpoints such as CTLA-4 and PD-1/PD-L1 (70). This evidence concerns the gene CTLA4 and neoplasm.